S&P 500
7,712.75
+46.15
+0.60%
Dow
53,486.39
+424.44
+0.80%
Nasdaq
26,436.82
+218.99
+0.84%
NYSE Composite
24,495.55
+0.00
+0.00%
Russell 2000
2,953.17
+33.04
+1.13%
VIX
15.02
-0.18
-1.18%
ROIV · Roivant Sciences Ltd. Common Shares
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Roivant Sciences Ltd (ROIV)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$33.99
-0.20
(-0.60%)
● Market open
DAY'S RANGE
$33.99
$33.70
$33.99
52-WEEK RANGE
$33.99
$12.28
$37.97
What's happening
- ROIV is down 0.60% today, trading at $33.99. — Live quote
- Volume today (2,713) is well below its 3-month average of 6,198,310. (Finnhub fundamentals)
- Last quarter's EPS beat estimates: $-0.26 actual vs. $-0.34 estimated (+22.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ROIV
+57.51%
vs S&P 500
+45.30%
1-YEAR RETURN
ROIV
+171.49%
vs S&P 500
+152.62%
6-MONTH RETURN
ROIV
+18.11%
3-MONTH RETURN
ROIV
+20.99%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-08-06 (Q1 2027)
$-0.26
Est. $-0.34
BEAT +22.6%
2026-04-26 (Q4 2026)
$-0.58
Est. $-0.35
MISS -64.6%
2026-01-26 (Q3 2026)
$-0.38
Est. $-0.32
MISS -17.3%
2025-10-26 (Q2 2026)
$-0.17
Est. $-0.34
BEAT +50.1%
Valuation Measures & Ratios
Enterprise Value4$24.96B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)3479.27
Price / Book76.02
EV4 / Revenue3313.52
EV4 / EBITDA5.69
Profit Margin-3534.96%
Operating Margin-7768.35%
Return on Equity (ROE8)-6.12%
Return on Assets (ROA9)-5.00%
Avg Volume (3M)6,198,310
Quarterly history (5 periods)
| Measure | Jun '26 | Dec '25 | Sep '25 | Jun '25 | Dec '24 |
|---|---|---|---|---|---|
| Market cap | $25.85B | $15.18B | $10.10B | $7.63B | $8.71B |
| P/E | -32.61 | -35.02 | -25.40 | -40.39 | 1.70 |
| Price/Sales | 3598.86 | 1028.38 | 586.04 | 322.49 | 235.18 |
| Price/Book | 6.11 | 3.55 | 2.32 | 1.76 | 1.68 |
| EV/Revenue | 3425.03 | 928.21 | 514.26 | 270.13 | 181.44 |
| EV/EBITDA | -19.02 | -11.42 | -7.40 | — | — |
| ROE | -18.73% | -10.15% | -9.12% | -4.35% | 98.87% |
| ROA | -14.94% | -8.29% | -7.86% | -3.75% | 88.58% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short30,601,726
Change from Prior Settlement-13.15%
% of Float—
Days to Cover (Short Ratio)5.01
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Loading chart…
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +171.5%. Finnhub market metrics ↗
- Latest SEC filing is Form 4, filed 2026-09-01; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -33.5% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -3535.0%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ROIV
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Dec '25 | Sep '25 | Jun '25 | Dec '24 | Sep '24 | Jun '24 | Dec '23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $2.0M | $1.6M | $2.2M | $9.0M | $4.5M | $8.0M | $15.6M |
| Operating income | -$366.0M | -$339.2M | -$306.2M | -$284.9M | -$274.4M | -$341.7M | -$102.2M | $5.13B |
| Net income | -$189.8M | -$265.9M | -$113.5M | -$223.4M | $169.4M | -$230.2M | $95.3M | $5.10B |
| EPS (diluted) | $-0.26 | $-0.38 | $-0.17 | $-0.33 | $0.23 | $-0.31 | $0.12 | $6.03 |
| EPS (basic) | $-0.26 | $-0.38 | $-0.17 | $-0.33 | $0.23 | $-0.31 | $0.13 | $6.37 |
| Operating margin | -$25.4K | -$17.0K | -$19.5K | -$13.1K | -$3.0K | -$7.6K | -$1.3K | $32.9K |
| Net margin | -$13.2K | -$13.3K | -$7.2K | -$10.3K | $1.9K | -$5.1K | $1.2K | $32.7K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $5.31B | $5.71B | $5.23B | $5.06B | $5.03B | $5.44B | $5.79B | $6.21B |
| Total liabilities | $384.6M | $416.3M | $251.1M | $257.1M | $216.7M | $249.7M | $256.4M | $626.0M |
| Stockholders' equity | $4.23B | $4.53B | $4.27B | $4.36B | $4.35B | $4.69B | $5.19B | $5.15B |
| Total current assets | $4.74B | $5.17B | $4.66B | $4.51B | $4.62B | $5.00B | $5.36B | $5.80B |
| Total current liabilities | $283.6M | $281.2M | $152.0M | $133.9M | $113.9M | $149.4M | $141.5M | $556.2M |
| Cash & equivalents | $1.25B | $1.42B | $1.48B | $1.24B | $1.24B | $2.72B | $1.99B | $1.96B |
| Marketable securities (current) | $2.59B | $2.87B | $3.05B | $3.15B | $3.26B | $2.17B | $3.16B | $3.43B |
| Accounts receivable | — | — | — | — | — | — | $678.0K | $1.9M |
| Inventory | — | — | — | — | — | — | — | — |
| Other current assets | $128.4M | $105.3M | $129.9M | $125.8M | $112.6M | $113.2M | $217.5M | $94.2M |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $11.3M | $12.0M | $13.4M | $25.7M | $14.9M | $12.1M | $13.6M | $13.7M |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | $29.6M | $40.9M | $34.6M | $27.8M | $31.1M | $32.9M | $33.9M | $36.9M |
| Accounts payable | $25.1M | $18.0M | $13.3M | $15.1M | $11.6M | $23.7M | $23.7M | $25.1M |
| Accrued liabilities | $168.7M | $205.8M | $118.0M | $108.3M | $88.7M | $114.3M | $104.3M | $111.5M |
| Deferred revenue (current) | — | — | $3.0M | — | — | $1.2M | $3.0M | $3.4M |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | $3.2M | $583.0K | $10.2M | $1.5M | $4.2M | $1.2M | $3.6M | $8.9M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $6.3M | $70.0K | $677.0K | $170.0K | $228.0K | $22.0K | $307.0K | $295.0K |
| Common stock & paid-in capital | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Retained earnings | -$900.4M | -$501.8M | -$695.0M | -$429.1M | -$315.6M | $116.1M | $460.4M | $395.6M |
| Accumulated other comprehensive income (loss) | $701.0K | $4.4M | $20.6M | $19.6M | $17.1M | $9.4M | $8.1M | -$18.0M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$270.5M | -$163.8M | -$196.5M | -$185.7M | -$204.4M | -$172.6M | -$207.3M | -$266.8M |
| Investing cash flow | $281.3M | $173.5M | $109.5M | $120.4M | -$1.09B | $1.07B | $454.1M | -$3.29B |
| Financing cash flow | -$181.5M | -$68.8M | $328.2M | $62.6M | -$187.8M | -$177.2M | -$273.0M | -$109.1M |
| Free cash flow | -$270.9M | -$165.1M | -$191.5M | -$193.5M | -$208.4M | -$173.4M | -$209.1M | -$267.8M |
| Capital expenditures | $419.0K | $1.3M | -$4.9M | $7.8M | $4.0M | $811.0K | $1.8M | $996.0K |
| Depreciation & amortization | $600.0K | $638.0K | $691.0K | $921.0K | $1.1M | $1.4M | $2.9M | $4.8M |
| Share-based compensation | $83.3M | $77.2M | $105.0M | $81.8M | $82.2M | $83.5M | $83.7M | $71.7M |
| Deferred income taxes | — | $0 | — | — | — | $0 | — | — |
| Purchases of investments | $286.5M | $2.99B | — | — | $1.80B | $0 | — | — |
| Sales/maturities of investments | $568.2M | $1.12B | — | — | $0 | $0 | — | — |
| Other investing activities | — | $0 | $2.5M | — | — | -$79.0K | $0 | $0 |
| Share repurchases | $206.7M | — | $0 | $0 | $208.3M | $295.4M | $243.3M | $106.1M |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 |
|---|---|---|---|---|---|
| Revenue | $8.3M | $29.1M | $32.7M | $31.5M | $55.3M |
| Operating income | -$515.1M | -$1.00B | $4.50B | -$906.8M | -$1.35B |
| Net income | -$299.8M | -$172.0M | $4.35B | -$1.01B | -$845.3M |
| EPS (diluted) | $-0.54 | $-0.24 | $5.23 | $-1.42 | $-1.26 |
| EPS (basic) | $-0.43 | $-0.24 | $5.55 | $-1.42 | $-1.26 |
| Operating margin | -$6.2K | -$3.5K | $13.7K | -$2.9K | -$2.4K |
| Net margin | -$3.6K | -$592 | $13.3K | -$3.2K | -$1.5K |
Balance sheet
| Line item | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 |
|---|---|---|---|---|---|
| Total assets | $5.71B | $5.44B | $7.22B | $2.39B | $2.59B |
| Total liabilities | $416.3M | $249.7M | $774.0M | $782.0M | $523.7M |
| Stockholders' equity | $4.53B | $4.69B | $5.97B | $1.16B | $1.66B |
| Total current assets | $5.17B | $5.00B | $6.73B | $1.80B | $2.15B |
| Total current liabilities | $281.2M | $149.4M | $266.8M | $272.4M | $184.4M |
| Cash & equivalents | $1.42B | $2.72B | $6.49B | $1.68B | $2.06B |
| Marketable securities (current) | $2.87B | $2.17B | $0 | — | — |
| Accounts receivable | — | — | $53.5M | $30.4M | $3.9M |
| Inventory | — | — | $35.3M | $2.8M | $0 |
| Other current assets | $105.3M | $113.2M | $80.6M | $121.8M | $86.1M |
| Marketable securities (non-current) | — | — | — | — | $0 |
| Property, plant & equipment | $12.0M | $12.1M | $15.3M | $39.1M | $25.9M |
| Intangible assets | — | — | $137.8M | $144.9M | $0 |
| Other non-current assets | $40.9M | $32.9M | $37.7M | $49.5M | $25.8M |
| Accounts payable | $18.0M | $23.7M | $14.0M | $37.8M | $34.6M |
| Accrued liabilities | $205.8M | $114.3M | $119.4M | $167.1M | $127.5M |
| Deferred revenue (current) | — | $1.2M | $4.2M | $12.4M | $10.1M |
| Short-term debt | — | — | $12.0M | $40.7M | $0 |
| Other current liabilities | $583.0K | $1.2M | $13.9M | $15.1M | $10.9M |
| Long-term debt | — | — | $430.6M | $375.5M | $210.0M |
| Other non-current liabilities | $70.0K | $22.0K | $2.5M | $17.0M | $21.9M |
| Common stock & paid-in capital | $0 | $0 | $0 | $0 | $0 |
| Retained earnings | -$501.8M | $116.1M | $576.2M | -$3.77B | -$2.76B |
| Accumulated other comprehensive income (loss) | $4.4M | $9.4M | -$4.1M | -$2.6M | -$946.0K |
Cash flow
| Line item | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 |
|---|---|---|---|---|---|
| Operating cash flow | -$750.3M | -$839.5M | -$765.3M | -$843.4M | -$677.7M |
| Investing cash flow | -$682.3M | -$1.77B | $5.20B | -$44.3M | $303.3M |
| Financing cash flow | $134.2M | -$1.22B | $419.4M | $499.5M | $306.8M |
| Free cash flow | -$758.6M | -$844.0M | -$766.6M | -$856.1M | -$695.2M |
| Capital expenditures | $8.2M | $4.6M | $1.4M | $12.7M | $17.4M |
| Depreciation & amortization | $3.3M | $14.1M | $22.0M | $18.9M | $5.9M |
| Share-based compensation | $346.2M | $289.0M | $199.6M | $217.8M | $565.0M |
| Deferred income taxes | $0 | $0 | $0 | $0 | $0 |
| Purchases of investments | $4.80B | $0 | $0 | — | — |
| Sales/maturities of investments | $1.12B | $0 | $0 | — | — |
| Other investing activities | $2.5M | -$79.0K | -$8.6M | -$702.0K | -$600.0K |
| Share repurchases | — | $1.29B | $0 | $0 | — |
| Other financing activities | — | — | — | $0 | -$1.6M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ROIV as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-04-20 to 2026-08-28
Recent transactions
- Insiders have net sold 7,542,239 shares over the last 182 days, across 0 purchases and 35 sales.
- Most recent: Venker Eric (President & Immunovant CEO) — Option exercise of 200,000 shares on 2026-08-28.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)7,542,239 sh(35 txns)
Net Shares-7,542,239
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO | Option exercise | 2026-08-28 | 200,000 |
| Sukhatme Mayukh | President & CIO | Option exercise | 2026-08-21 | 144,756 |
| Pulik Richard | CFO | Tax withholding | 2026-08-20 | 5,749 |
| MOMTAZEE JAMES C | Reporting person | Grant / award | 2026-07-17 | 405 |
| Epperly Melissa B, | Reporting person | Grant / award | 2026-07-17 | 543 |
| Oren Ilan | Reporting person | Grant / award | 2026-07-17 | 775 |
| Gline Matthew | CEO | Tax withholding | 2026-06-30 | 76,171 |
| Fitzgerald Meghan | Director | Option exercise | 2026-06-30 | 10,000 |
| Torti Frank | President and Vant Chair | Tax withholding | 2026-06-30 | 40,310 |
| MANCHESTER KEITH S | Reporting person | Open market sale | 2026-06-30 | 12,380 |
| Gold Daniel Allen | Reporting person | Open market sale | 2026-06-30 | 12,380 |
| QVT Financial LP | Reporting person | Open market sale | 2026-06-30 | 12,380 |
| Humes Jennifer | Chief Accounting Officer | Tax withholding | 2026-06-20 | 3,582 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-28 | Venker Eric | President & Immunovant CEO | Option exercise | 200,000 | $3.85 |
| 2026-08-28 | Venker Eric | President & Immunovant CEO | Open market sale | 166,182 | $35.63 |
| 2026-08-28 | Venker Eric | President & Immunovant CEO | Open market sale | 33,818 | $36.44 |
| 2026-08-21 | Sukhatme Mayukh | President & CIO | Option exercise | 144,756 | $3.85 |
| 2026-08-21 | Sukhatme Mayukh | President & CIO | Open market sale | 144,756 | $36.48 |
| 2026-08-20 | Pulik Richard | CFO | Tax withholding | 5,749 | $36.84 |
| 2026-08-20 | Venker Eric | President & Immunovant CEO | Tax withholding | 13,909 | $36.84 |
| 2026-08-20 | Sukhatme Mayukh | President & CIO | Option exercise | 17,519 | $3.85 |
| 2026-08-20 | Sukhatme Mayukh | President & CIO | Open market sale | 17,519 | $37.30 |
| 2026-08-19 | Sukhatme Mayukh | President & CIO | Option exercise | 172,899 | $3.85 |
| 2026-08-19 | Sukhatme Mayukh | President & CIO | Open market sale | 172,899 | $37.17 |
| 2026-08-18 | Sukhatme Mayukh | President & CIO | Option exercise | 105,141 | $3.85 |
| 2026-08-18 | Sukhatme Mayukh | President & CIO | Open market sale | 105,141 | $36.59 |
| 2026-08-18 | Sukhatme Mayukh | President & CIO | Option exercise | 31,801 | $3.85 |
| 2026-08-18 | Sukhatme Mayukh | President & CIO | Open market sale | 31,801 | $37.18 |
| 2026-08-17 | Sukhatme Mayukh | President & CIO | Option exercise | 284,707 | $3.85 |
| 2026-08-17 | Sukhatme Mayukh | President & CIO | Open market sale | 284,707 | $36.25 |
| 2026-08-14 | Sukhatme Mayukh | President & CIO | Option exercise | 243,177 | $3.85 |
| 2026-08-14 | Sukhatme Mayukh | President & CIO | Open market sale | 243,177 | $36.23 |
| 2026-07-27 | Venker Eric | President & Immunovant CEO | Option exercise | 200,000 | $3.85 |
| 2026-07-27 | Venker Eric | President & Immunovant CEO | Open market sale | 200,000 | $34.95 |
| 2026-07-17 | MOMTAZEE JAMES C | Reporting person | Grant / award | 405 | $0.00 |
| 2026-07-17 | Epperly Melissa B, | Reporting person | Grant / award | 543 | $0.00 |
| 2026-07-17 | Oren Ilan | Reporting person | Grant / award | 775 | $0.00 |
| 2026-06-30 | Gline Matthew | CEO | Tax withholding | 76,171 | $35.39 |
| 2026-06-30 | Fitzgerald Meghan | Director | Option exercise | 10,000 | $8.80 |
| 2026-06-30 | Fitzgerald Meghan | Director | Open market sale | 10,000 | $34.90 |
| 2026-06-30 | Torti Frank | President and Vant Chair | Tax withholding | 40,310 | $35.39 |
| 2026-06-30 | Sukhatme Mayukh | President & CIO | Tax withholding | 46,878 | $35.39 |
| 2026-06-30 | MANCHESTER KEITH S | Reporting person | Open market sale | 12,380 | $35.28 |
| 2026-06-30 | MANCHESTER KEITH S | Reporting person | Open market sale | 200,000 | $35.45 |
| 2026-06-30 | Gold Daniel Allen | Reporting person | Open market sale | 12,380 | $35.28 |
| 2026-06-30 | QVT Financial LP | Reporting person | Open market sale | 12,380 | $35.28 |
| 2026-06-29 | Epperly Melissa B, | Director | Option exercise | 17,750 | $4.46 |
| 2026-06-29 | Epperly Melissa B, | Director | Open market sale | 15,002 | $34.32 |
| 2026-06-29 | Epperly Melissa B, | Director | Open market sale | 2,748 | $34.71 |
| 2026-06-29 | MANCHESTER KEITH S | Reporting person | Open market sale | 200,000 | $34.44 |
| 2026-06-29 | MANCHESTER KEITH S | Reporting person | Open market sale | 600,000 | $34.59 |
| 2026-06-29 | Gold Daniel Allen | Reporting person | Open market sale | 200,000 | $34.44 |
| 2026-06-29 | Gold Daniel Allen | Reporting person | Open market sale | 600,000 | $34.59 |
| 2026-06-29 | QVT Financial LP | Reporting person | Open market sale | 200,000 | $34.44 |
| 2026-06-29 | QVT Financial LP | Reporting person | Open market sale | 600,000 | $34.59 |
| 2026-06-26 | MANCHESTER KEITH S | Reporting person | Open market sale | 300,783 | $33.92 |
| 2026-06-26 | MANCHESTER KEITH S | Reporting person | Open market sale | 325,000 | $34.07 |
| 2026-06-26 | Gold Daniel Allen | Reporting person | Open market sale | 300,783 | $33.92 |
| 2026-06-26 | Gold Daniel Allen | Reporting person | Open market sale | 325,000 | $34.07 |
| 2026-06-26 | QVT Financial LP | Reporting person | Open market sale | 300,783 | $33.92 |
| 2026-06-26 | QVT Financial LP | Reporting person | Open market sale | 325,000 | $34.07 |
| 2026-06-26 | Sukhatme Mayukh | President & CIO | Option exercise | 500,000 | $3.85 |
| 2026-06-26 | Sukhatme Mayukh | President & CIO | Open market sale | 500,000 | $34.08 |
| 2026-06-25 | Sukhatme Mayukh | President & CIO | Option exercise | 500,000 | $3.85 |
| 2026-06-25 | Sukhatme Mayukh | President & CIO | Open market sale | 500,000 | $34.13 |
| 2026-06-24 | Venker Eric | President & Immunovant CEO | Option exercise | 200,000 | $3.85 |
| 2026-06-24 | Venker Eric | President & Immunovant CEO | Open market sale | 153,766 | $33.05 |
| 2026-06-24 | Venker Eric | President & Immunovant CEO | Open market sale | 46,234 | $33.51 |
| 2026-06-20 | Pulik Richard | CFO | Tax withholding | 2,129 | $31.43 |
| 2026-06-20 | Humes Jennifer | Chief Accounting Officer | Tax withholding | 3,582 | $31.43 |
| 2026-05-22 | Venker Eric | President & Immunovant CEO | Option exercise | 200,000 | $3.85 |
| 2026-05-22 | Venker Eric | President & Immunovant CEO | Open market sale | 200,000 | $30.27 |
| 2026-05-20 | Venker Eric | President & Immunovant CEO | Tax withholding | 34,483 | $32.41 |
Showing the most recent 60 transactions.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 13:43 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-01 | 4 | 2026-08-28 | View on SEC.gov → |
| 2026-08-28 | 8-K | 2026-08-28 | View on SEC.gov → |
| 2026-08-27 | 8-K | 2026-08-27 | View on SEC.gov → |
| 2026-08-24 | 4 | 2026-08-20 | View on SEC.gov → |
| 2026-08-24 | 4 | 2026-08-20 | View on SEC.gov → |
| 2026-08-21 | 4 | 2026-08-19 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-14 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-27 | View on SEC.gov → |
| 2026-07-21 | 4 | 2026-07-17 | View on SEC.gov → |
| 2026-07-21 | 4 | 2026-07-17 | View on SEC.gov → |
Recent news
Headlines about ROIV (Roivant Sciences Ltd. Common Shares). Links open the publisher — we don’t host full articles.
-
FDA Clears First Targeted Dermatomyositis Treatment From Roivant
Benzinga · 2026-08-31 -
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis - Slideshow
SeekingAlpha · 2026-08-30 -
Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately
Yahoo · 2026-08-28 -
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis Transcript
SeekingAlpha · 2026-08-28 -
Pfizer-backed Priovant wins FDA approval for lead asset
Seeking Alpha · 2026-08-28 -
HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $41 Price Target
Benzinga · 2026-08-28 -
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Yahoo · 2026-08-27 -
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Yahoo · 2026-08-27
No headlines in this category right now — try “All”.